|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2019
|
|
|
Less Than 12 Months
|
|
12 Months or Longer
|
|
Total
|
(in thousands)
|
|
Fair
Value
|
|
Unrealized
Losses
|
|
Fair
Value
|
|
Unrealized
Losses
|
|
Fair
Value
|
|
Unrealized
Losses
|
Securities available-for-sale
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Government-sponsored agencies
|
|
$
|
4,820
|
|
|
$
|
(61
|
)
|
|
$
|
62,182
|
|
|
$
|
(1,881
|
)
|
|
$
|
67,002
|
|
|
$
|
(1,942
|
)
|
Municipal securities
|
|
1,279
|
|
|
(1,501
|
)
|
|
—
|
|
|
—
|
|
|
1,279
|
|
|
(1,501
|
)
|
Agency mortgage-backed securities
|
|
91,159
|
|
|
(829
|
)
|
|
83,212
|
|
|
(3,177
|
)
|
|
174,371
|
|
|
(4,006
|
)
|
Private label mortgage-backed securities
|
|
30,077
|
|
|
(180
|
)
|
|
2,884
|
|
|
(8
|
)
|
|
32,961
|
|
|
(188
|
)
|
Asset-backed securities
|
|
—
|
|
|
—
|
|
|
4,955
|
|
|
(45
|
)
|
|
4,955
|
|
|
(45
|
)
|
Corporate securities
|
|
—
|
|
|
—
|
|
|
22,985
|
|
|
(1,532
|
)
|
|
22,985
|
|
|
(1,532
|
)
|
Total
|
|
$
|
127,335
|
|
|
$
|
(2,571
|
)
|
|
$
|
176,218
|
|
|
$
|
(6,643
|
)
|
|
$
|
303,553
|
|
|
$
|
(9,214
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2019
|
|
|
Less Than 12 Months
|
|
12 Months or Longer
|
|
Total
|
(in thousands)
|
|
Fair
Value
|
|
Unrealized
Losses
|
|
Fair
Value
|
|
Unrealized
Losses
|
|
Fair
Value
|
|
Unrealized
Losses
|
Securities held-to-maturity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate securities
|
|
13,977
|
|
|
(132
|
)
|
|
—
|
|
|
—
|
|
|
13,977
|
|
|
(132
|
)
|
Total
|
|
$
|
13,977
|
|
|
$
|
(132
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
13,977
|
|
|
$
|
(132
|
)
|
There were no amounts reclassified from accumulated other comprehensive loss to the condensed consolidated statements of income during the three months ended March 31, 2019. Amounts reclassified from accumulated other comprehensive loss and the affected line items in the condensed consolidated statements of income during the three months ended March 31, 2020 were as follows:
|
|
|
|
|
|
|
|
(in thousands)
Details About Accumulated Other Comprehensive Loss Components
|
|
|
|
Affected Line Item in the
Statements of Income
|
|
Three Months Ended March 31, 2020
|
|
Realized gains on securities available-for-sale
|
|
|
|
|
|
Gain realized in earnings
|
|
$
|
41
|
|
|
Gain on sale of securities
|
Total reclassified amount before tax
|
|
41
|
|
|
Income Before Income Taxes
|
Tax expense
|
|
11
|
|
|
Income Tax Provision
|
Total reclassifications out of accumulated other comprehensive loss
|
|
$
|
30
|
|
|
Net Income
|
Note 4: Loans
Loan balances as of March 31, 2020 and December 31, 2019 are summarized in the table below.
Categories of loans include:
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
March 31, 2020
|
|
December 31, 2019
|
Commercial loans
|
|
|
|
|
|
|
Commercial and industrial
|
|
$
|
95,227
|
|
|
$
|
96,420
|
|
Owner-occupied commercial real estate
|
|
74,737
|
|
|
73,392
|
|
Investor commercial real estate
|
|
13,421
|
|
|
12,567
|
|
Construction
|
|
64,581
|
|
|
60,274
|
|
Single tenant lease financing
|
|
972,275
|
|
|
995,879
|
|
Public finance
|
|
627,678
|
|
|
687,094
|
|
Healthcare finance
|
|
372,266
|
|
|
300,612
|
|
Small business lending
|
|
67,275
|
|
|
60,279
|
|
Total commercial loans
|
|
2,287,460
|
|
|
2,286,517
|
|
Consumer loans
|
|
|
|
|
Residential mortgage
|
|
218,730
|
|
|
313,849
|
|
Home equity
|
|
23,855
|
|
|
24,306
|
|
Other consumer
|
|
296,605
|
|
|
295,309
|
|
Total consumer loans
|
|
539,190
|
|
|
633,464
|
|
Total commercial and consumer loans
|
|
2,826,650
|
|
|
2,919,981
|
|
Net deferred loan origination costs and premiums and discounts on purchased loans and other(1)
|
|
65,443
|
|
|
43,566
|
|
Total loans
|
|
2,892,093
|
|
|
2,963,547
|
|
Allowance for loan losses
|
|
(22,857
|
)
|
|
(21,840
|
)
|
Net loans
|
|
$
|
2,869,236
|
|
|
$
|
2,941,707
|
|
(1) Includes carrying value adjustments of $44.6 million and $21.4 million as of March 31, 2020 and December 31, 2019, respectively, related to interest rate swaps associated with public finance loans.
The risk characteristics of each loan portfolio segment are as follows:
Commercial and Industrial: Commercial and industrial loans’ sources of repayment are primarily based on the identified cash flows of the borrower and secondarily on the underlying collateral provided by the borrower. The cash flows of borrowers, however, may not be as expected, and the collateral securing these loans may fluctuate in value. Loans are made for working capital, equipment purchases, or other purposes. Most commercial and industrial loans are secured by the assets being financed and may incorporate a personal guarantee. This portfolio segment is generally concentrated in Central Indiana and adjacent markets and the greater Phoenix, Arizona market.
Owner-Occupied Commercial Real Estate: The primary source of repayment is the cash flow from the ongoing operations and activities conducted by the borrower, or an affiliate of the borrower, who owns the property. This portfolio segment is generally concentrated in Central Indiana and adjacent markets and the greater Phoenix, Arizona market and its loans are often secured by manufacturing and service facilities, as well as office buildings.
Investor Commercial Real Estate: These loans are underwritten primarily based on the cash flow expected to be generated from the property and are secondarily supported by the value of the real estate. These loans typically incorporate a personal guarantee from the primary sponsor or sponsors. This portfolio segment generally involves larger loan amounts with repayment primarily dependent on the successful leasing and operation of the property securing the loan or the business conducted on the property securing the loan. Investor commercial real estate loans may be more adversely affected by changing economic conditions in the real estate markets, industry dynamics or the overall health of the local economy where the property is located. The properties securing the Company’s investor commercial real estate portfolio tend to be diverse in terms of property type and are generally located in the state of Indiana or markets immediately adjacent to Indiana. Management monitors and evaluates commercial real estate loans based on property financial performance, collateral value, guarantor strength, economic and industry conditions together with other risk grade criteria. As a general rule, the Company avoids financing special use projects or properties outside of its designated market areas unless other underwriting factors are present to mitigate these additional risks.
Construction: Construction loans are secured by land and related improvements and are made to assist in the construction of new structures, which may include commercial (retail, industrial, office, multi-family) properties or single family residential properties offered for sale by the builder. These loans generally finance a variety of project costs, including land, site preparation, architectural services, construction, closing and soft costs and interim financing needs. The cash flows of builders, while initially predictable, may fluctuate with market conditions, and the value of the collateral securing these loans may be subject to fluctuations based on general economic changes. This portfolio segment is generally concentrated in Central Indiana.
Single Tenant Lease Financing: These loans are made on a nationwide basis to property owners of real estate subject to long-term lease arrangements with single tenant operators. The real estate is typically operated by regionally, nationally or globally branded businesses. The loans are underwritten based on the financial strength of the borrower, characteristics of the real estate, cash flows generated from the lease arrangements and the financial strength of the tenant. Similar to the other loan portfolio segments, management monitors and evaluates these loans based on borrower and tenant financial performance, collateral value, industry trends and other risk grade criteria.
Public Finance: These loans are made to governmental and not-for-profit entities to provide both tax-exempt and taxable loans for a variety of purposes including: short-term cash-flow needs; debt refinancing; economic development; quality of life projects; infrastructure improvements; and equipment financing. The primary sources of repayment for public finance loans include pledged revenue sources including but not limited to: general obligations; property taxes; income taxes; tax increment revenue; utility revenue; gaming revenues; sales tax; and pledged general revenue. Certain loans may also include an additional collateral pledge of mortgaged property or a security interest in financed equipment. Public finance loans have been completed primarily in the Midwest, with plans to continue expanding nationwide.
Healthcare Finance: These loans are made to healthcare providers, primarily dentists, for practice acquisition refinancing that occasionally includes owner-occupied commercial real estate and equipment purchases. The sources of repayment are primarily based on the identified cash flows from operations of the borrower and related entities if the real estate is held in a separate entity and secondarily on the underlying collateral provided by the borrower. This portfolio segment was initially concentrated in the Western United States but has been growing rapidly throughout the rest of the country with the addition of a growing sales force located in Eastern and Midwestern markets.
Small Business Lending: These loans are to small businesses and generally carry a partial guaranty from the U.S. Small Business Administration ("SBA"). We generally sell the government guaranteed portion of SBA loans into the secondary market while retaining the non-guaranteed portion of the loan and the servicing rights. Loans in the small business lending portfolio have sources of repayment that are primarily based on the identified cash flows of the borrower and secondarily on any underlying collateral provided by the borrower. Loans may, but do not always, have a collateral shortfall. For SBA loans where the guaranteed portion is retained, the SBA guaranty provides a tertiary source of repayment to the Bank in event of borrower default. Cash flows of borrowers, however, may not be as expected and collateral securing these loans may fluctuate in value. Loans are made for a broad array of purposes including, but not limited to, providing operating cash flow, funding ownership changes, and facilitating equipment purchases. This portfolio segment has an emerging geography, with a nationwide focus.
Residential Mortgage: With respect to residential loans that are secured by 1-to-4 family residences and are generally owner occupied, the Company typically establishes a maximum loan-to-value ratio and requires private mortgage insurance if that ratio is exceeded. Repayment of these loans is primarily dependent on the financial circumstances of the borrowers, which can be impacted by economic conditions in their market areas such as unemployment levels. Repayment can also
be impacted by changes in residential property values. Risk is mitigated by the fact that the loans are of smaller individual amounts and spread over a large number of borrowers in geographically diverse locations throughout the country.
Home Equity: Home equity loans and lines of credit are typically secured by a subordinate interest in 1-to-4 family residences. The properties securing the home equity portfolio segment are generally geographically diverse as the Company offers these products on a nationwide basis. Repayment of these loans and lines of credit is primarily dependent on the financial circumstances of the borrowers and may be impacted by changes in unemployment levels and property values on residential properties, among other economic conditions in the market.
Other Consumer: These loans primarily consist of consumer loans and credit cards. Consumer loans may be secured by consumer assets such as horse trailers or recreational vehicles. Some consumer loans are unsecured, such as small installment loans, home improvement loans and certain lines of credit. Repayment of consumer loans is primarily dependent upon the personal income of the borrowers, which can be impacted by economic conditions in their market areas such as unemployment levels. Risk is mitigated by the fact that the loans are of smaller individual amounts and spread over a large number of borrowers in geographically diverse locations throughout the country.
Allowance for Loan Losses Methodology
Company policy is designed to maintain an adequate allowance for loan losses (“ALLL”). The portfolio is segmented by loan type, and the required ALLL for types of performing homogeneous loans which do not have a specific reserve is determined by applying a factor based on average historical losses, adjusted for current economic factors and portfolio trends. Management adds qualitative factors for observable trends, changes in internal practices, changes in delinquencies and impairments, and external factors. Observable factors include changes in the composition and size of portfolios, as well as loan terms or concentration levels. The Company evaluates the impact of internal changes such as management and staff experience levels or modification to loan underwriting processes. Delinquency trends are scrutinized for both volume and severity of past due, nonaccrual, or classified loans, as well as any changes in the value of underlying collateral. Finally, the Company considers the effect of other external factors such as national, regional, and local economic and business conditions, as well as competitive, legal, and regulatory requirements. Loans that are considered to be impaired are evaluated to determine the need for a specific allowance by applying at least one of three methodologies: present value of future cash flows; fair value of collateral less costs to sell; or the loan’s observable market price. All troubled debt restructurings (“TDR”) are considered impaired loans. Loans evaluated for impairment are removed from other pools to prevent double-counting. Accounting Standards Codification (“ASC”) Topic 310, Receivables, requires that impaired loans be measured based on the present value of expected future cash flows discounted at the loans’ effective interest rates or the fair value of the underlying collateral less costs to sell and allows existing methods for recognizing interest income.
Provision for Loan Losses
A provision for estimated losses on loans is charged to income based upon management’s evaluation of the potential losses. Such an evaluation, which includes a review of all loans for which full repayment may not be reasonably assured, considers, among other matters, the estimated net realizable value of the underlying collateral, as applicable, economic conditions, loan loss experience, and other factors that are particularly susceptible to changes that could result in a material adjustment in the near term. While management attempts to use the best information available in making its evaluations, future allowance adjustments may be necessary if economic conditions change substantially from the assumptions used in making the evaluations.
Policy for Charging Off Loans
The Company’s policy is to charge off a loan at any point in time when it no longer can be considered a bankable asset, meaning collectible within the parameters of policy. A secured loan is generally charged down to the estimated fair value of the collateral, less costs to sell, no later than when it is 120 days past due as to principal or interest. An unsecured loan generally is charged off no later than when it is 180 days past due as to principal or interest. A home improvement loan generally is charged off no later than when it is 90 days past due as to principal or interest.
The following tables present changes in the balance of the ALLL during the three months ended March 31, 2020 and 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
Three Months Ended March 31, 2020
|
Allowance for loan losses:
|
Balance, Beginning of Period
|
|
Provision (Credit) Charged to Expense
|
|
Losses
Charged Off
|
|
Recoveries
|
|
Balance,
End of Period
|
Commercial and industrial
|
$
|
1,521
|
|
|
$
|
346
|
|
|
$
|
(197
|
)
|
|
$
|
—
|
|
|
$
|
1,670
|
|
Owner-occupied commercial real estate
|
561
|
|
|
84
|
|
|
—
|
|
|
—
|
|
|
645
|
|
Investor commercial real estate
|
109
|
|
|
19
|
|
|
—
|
|
|
—
|
|
|
128
|
|
Construction
|
380
|
|
|
80
|
|
|
—
|
|
|
—
|
|
|
460
|
|
Single tenant lease financing
|
11,175
|
|
|
(420
|
)
|
|
—
|
|
|
—
|
|
|
10,755
|
|
Public finance
|
1,580
|
|
|
(97
|
)
|
|
—
|
|
|
—
|
|
|
1,483
|
|
Healthcare finance
|
3,247
|
|
|
1,071
|
|
|
—
|
|
|
—
|
|
|
4,318
|
|
Small business lending
|
54
|
|
|
203
|
|
|
—
|
|
|
8
|
|
|
265
|
|
Residential mortgage
|
657
|
|
|
(143
|
)
|
|
(15
|
)
|
|
1
|
|
|
500
|
|
Home equity
|
46
|
|
|
5
|
|
|
—
|
|
|
2
|
|
|
53
|
|
Other consumer
|
2,510
|
|
|
313
|
|
|
(286
|
)
|
|
43
|
|
|
2,580
|
|
Total
|
$
|
21,840
|
|
|
$
|
1,461
|
|
|
$
|
(498
|
)
|
|
$
|
54
|
|
|
$
|
22,857
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
Three Months Ended March 31, 2019
|
Allowance for loan losses:
|
Balance, Beginning of Period
|
|
Provision (Credit) Charged to Expense
|
|
Losses
Charged Off
|
|
Recoveries
|
|
Balance,
End of Period
|
Commercial and industrial
|
$
|
1,384
|
|
|
$
|
79
|
|
|
$
|
(112
|
)
|
|
$
|
—
|
|
|
$
|
1,351
|
|
Owner-occupied commercial real estate
|
783
|
|
|
(38
|
)
|
|
—
|
|
|
—
|
|
|
745
|
|
Investor commercial real estate
|
61
|
|
|
42
|
|
|
—
|
|
|
—
|
|
|
103
|
|
Construction
|
251
|
|
|
16
|
|
|
—
|
|
|
—
|
|
|
267
|
|
Single tenant lease financing
|
8,827
|
|
|
541
|
|
|
—
|
|
|
—
|
|
|
9,368
|
|
Public finance
|
1,670
|
|
|
(20
|
)
|
|
—
|
|
|
—
|
|
|
1,650
|
|
Healthcare finance
|
1,264
|
|
|
467
|
|
|
—
|
|
|
—
|
|
|
1,731
|
|
Small business lending
|
203
|
|
|
(8
|
)
|
|
—
|
|
|
—
|
|
|
195
|
|
Residential mortgage
|
1,079
|
|
|
(36
|
)
|
|
—
|
|
|
1
|
|
|
1,044
|
|
Home equity
|
53
|
|
|
(6
|
)
|
|
—
|
|
|
2
|
|
|
49
|
|
Other consumer
|
2,321
|
|
|
248
|
|
|
(317
|
)
|
|
86
|
|
|
2,338
|
|
Total
|
$
|
17,896
|
|
|
$
|
1,285
|
|
|
$
|
(429
|
)
|
|
$
|
89
|
|
|
$
|
18,841
|
|
The following tables present the recorded investment in loans based on portfolio segment and impairment method as of March 31, 2020 and December 31, 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
Loans
|
|
Allowance for Loan Losses
|
March 31, 2020
|
Ending Balance:
Collectively Evaluated for Impairment
|
|
Ending Balance:
Individually Evaluated for Impairment
|
|
Ending Balance
|
|
Ending Balance:
Collectively Evaluated for Impairment
|
|
Ending Balance:
Individually Evaluated for Impairment
|
|
Ending Balance
|
Commercial and industrial
|
$
|
94,329
|
|
|
$
|
898
|
|
|
$
|
95,227
|
|
|
$
|
1,561
|
|
|
$
|
109
|
|
|
$
|
1,670
|
|
Owner-occupied commercial real estate
|
74,142
|
|
|
595
|
|
|
74,737
|
|
|
645
|
|
|
—
|
|
|
645
|
|
Investor commercial real estate
|
13,421
|
|
|
—
|
|
|
13,421
|
|
|
128
|
|
|
—
|
|
|
128
|
|
Construction
|
64,581
|
|
|
—
|
|
|
64,581
|
|
|
460
|
|
|
—
|
|
|
460
|
|
Single tenant lease financing
|
967,595
|
|
|
4,680
|
|
|
972,275
|
|
|
9,095
|
|
|
1,660
|
|
|
10,755
|
|
Public finance
|
627,678
|
|
|
—
|
|
|
627,678
|
|
|
1,483
|
|
|
—
|
|
|
1,483
|
|
Healthcare finance
|
372,266
|
|
|
—
|
|
|
372,266
|
|
|
4,318
|
|
|
—
|
|
|
4,318
|
|
Small business lending
|
63,948
|
|
|
3,327
|
|
|
67,275
|
|
|
265
|
|
|
|
|
265
|
|
Residential mortgage
|
217,370
|
|
|
1,360
|
|
|
218,730
|
|
|
500
|
|
|
—
|
|
|
500
|
|
Home equity
|
23,855
|
|
|
—
|
|
|
23,855
|
|
|
53
|
|
|
—
|
|
|
53
|
|
Other consumer
|
296,557
|
|
|
48
|
|
|
296,605
|
|
|
2,580
|
|
|
—
|
|
|
2,580
|
|
Total
|
$
|
2,815,742
|
|
|
$
|
10,908
|
|
|
$
|
2,826,650
|
|
|
$
|
21,088
|
|
|
$
|
1,769
|
|
|
$
|
22,857
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
Loans
|
|
Allowance for Loan Losses
|
December 31, 2019
|
Ending Balance:
Collectively Evaluated for Impairment
|
|
Ending Balance:
Individually Evaluated for Impairment
|
|
Ending Balance
|
|
Ending Balance:
Collectively Evaluated for Impairment
|
|
Ending Balance:
Individually Evaluated for Impairment
|
|
Ending Balance
|
Commercial and industrial
|
$
|
93,520
|
|
|
$
|
2,900
|
|
|
$
|
96,420
|
|
|
$
|
1,412
|
|
|
$
|
109
|
|
|
$
|
1,521
|
|
Owner-occupied commercial real estate
|
71,067
|
|
|
2,325
|
|
|
73,392
|
|
|
561
|
|
|
—
|
|
|
561
|
|
Investor commercial real estate
|
12,567
|
|
|
—
|
|
|
12,567
|
|
|
109
|
|
|
—
|
|
|
109
|
|
Construction
|
60,274
|
|
|
—
|
|
|
60,274
|
|
|
380
|
|
|
—
|
|
|
380
|
|
Single tenant lease financing
|
991,199
|
|
|
4,680
|
|
|
995,879
|
|
|
9,515
|
|
|
1,660
|
|
|
11,175
|
|
Public finance
|
687,094
|
|
|
—
|
|
|
687,094
|
|
|
1,580
|
|
|
—
|
|
|
1,580
|
|
Healthcare finance
|
300,612
|
|
|
—
|
|
|
300,612
|
|
|
3,247
|
|
|
—
|
|
|
3,247
|
|
Small business lending
|
56,941
|
|
|
3,338
|
|
|
60,279
|
|
|
54
|
|
|
|
|
54
|
|
Residential mortgage
|
312,714
|
|
|
1,135
|
|
|
313,849
|
|
|
657
|
|
|
—
|
|
|
657
|
|
Home equity
|
24,306
|
|
|
—
|
|
|
24,306
|
|
|
46
|
|
|
—
|
|
|
46
|
|
Other consumer
|
295,266
|
|
|
43
|
|
|
295,309
|
|
|
2,510
|
|
|
—
|
|
|
2,510
|
|
Total
|
$
|
2,905,560
|
|
|
$
|
14,421
|
|
|
$
|
2,919,981
|
|
|
$
|
20,071
|
|
|
$
|
1,769
|
|
|
$
|
21,840
|
|
The Company utilizes a risk grading matrix to assign a risk grade to each of its commercial loans. A description of the general characteristics of the risk grades is as follows:
|
|
•
|
“Pass” - Higher quality loans that do not fit any of the other categories described below.
|
|
|
•
|
“Special Mention” - Loans that possess some credit deficiency or potential weakness, which deserve close attention.
|
|
|
•
|
“Substandard” - Loans that possess a defined weakness or weaknesses that jeopardize the liquidation of the debt. Loans characterized by the distinct possibility that the institution will sustain some loss if the deficiencies are not corrected. Loans that are inadequately protected by the current net worth and paying capacity of the obligor or of the collateral pledged, if any.
|
|
|
•
|
“Doubtful” - Such loans have been placed on nonaccrual status and may be heavily dependent upon collateral possessing a value that is difficult to determine or based upon some near-term event that lacks clear certainty. These loans have all of the weaknesses of those classified as Substandard; however, based on existing conditions, these weaknesses make full collection of the principal balance highly improbable.
|
|
|
•
|
“Loss” - Loans that are considered uncollectible and of such little value that continuing to carry them as assets is not warranted.
|
Nonaccrual Loans
Any loan which becomes 90 days delinquent or for which the full collection of principal and interest may be in doubt will be considered for nonaccrual status. At the time a loan is placed on nonaccrual status, all accrued but unpaid interest will be reversed from interest income. Placing the loan on nonaccrual status does not relieve the borrower of the obligation to repay interest. A loan placed on nonaccrual status may be restored to accrual status when all delinquent principal and interest has been brought current, and the Company expects full payment of the remaining contractual principal and interest.
The following tables present the credit risk profile of the Company’s commercial and consumer loan portfolios based on rating category and payment activity as of March 31, 2020 and December 31, 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2020
|
(in thousands)
|
Pass
|
|
Special Mention
|
|
Substandard
|
|
Total
|
Commercial and industrial
|
$
|
91,028
|
|
|
$
|
3,301
|
|
|
$
|
898
|
|
|
$
|
95,227
|
|
Owner-occupied commercial real estate
|
74,142
|
|
|
—
|
|
|
595
|
|
|
74,737
|
|
Investor commercial real estate
|
13,421
|
|
|
—
|
|
|
—
|
|
|
13,421
|
|
Construction
|
64,581
|
|
|
—
|
|
|
—
|
|
|
64,581
|
|
Single tenant lease financing
|
959,161
|
|
|
8,434
|
|
|
4,680
|
|
|
972,275
|
|
Public finance
|
627,678
|
|
|
—
|
|
|
—
|
|
|
627,678
|
|
Healthcare finance
|
371,203
|
|
|
1,063
|
|
|
—
|
|
|
372,266
|
|
Small business lending
|
62,226
|
|
|
1,722
|
|
|
3,327
|
|
|
67,275
|
|
Total commercial loans
|
$
|
2,263,440
|
|
|
$
|
14,520
|
|
|
$
|
9,500
|
|
|
$
|
2,287,460
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2020
|
(in thousands)
|
Performing
|
|
Nonaccrual
|
|
Total
|
Residential mortgage
|
$
|
217,739
|
|
|
$
|
991
|
|
|
$
|
218,730
|
|
Home equity
|
23,855
|
|
|
—
|
|
|
23,855
|
|
Other consumer
|
296,566
|
|
|
39
|
|
|
296,605
|
|
Total consumer loans
|
$
|
538,160
|
|
|
$
|
1,030
|
|
|
$
|
539,190
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2019
|
(in thousands)
|
Pass
|
|
Special Mention
|
|
Substandard
|
|
Total
|
Commercial and industrial
|
$
|
89,818
|
|
|
$
|
3,973
|
|
|
$
|
2,629
|
|
|
$
|
96,420
|
|
Owner-occupied commercial real estate
|
71,068
|
|
|
1,727
|
|
|
597
|
|
|
73,392
|
|
Investor commercial real estate
|
12,567
|
|
|
—
|
|
|
—
|
|
|
12,567
|
|
Construction
|
60,274
|
|
|
—
|
|
|
—
|
|
|
60,274
|
|
Single tenant lease financing
|
983,448
|
|
|
7,751
|
|
|
4,680
|
|
|
995,879
|
|
Public finance
|
687,094
|
|
|
—
|
|
|
—
|
|
|
687,094
|
|
Healthcare finance
|
300,612
|
|
|
—
|
|
|
—
|
|
|
300,612
|
|
Small business lending
|
55,206
|
|
|
1,735
|
|
|
3,338
|
|
|
60,279
|
|
Total commercial loans
|
$
|
2,260,087
|
|
|
$
|
15,186
|
|
|
$
|
11,244
|
|
|
$
|
2,286,517
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2019
|
(in thousands)
|
Performing
|
|
Nonaccrual
|
|
Total
|
Residential mortgage
|
$
|
313,088
|
|
|
$
|
761
|
|
|
$
|
313,849
|
|
Home equity
|
24,306
|
|
|
—
|
|
|
24,306
|
|
Other consumer
|
295,276
|
|
|
33
|
|
|
295,309
|
|
Total consumer loans
|
$
|
632,670
|
|
|
$
|
794
|
|
|
$
|
633,464
|
|
The following tables present the Company’s loan portfolio delinquency analysis as of March 31, 2020 and December 31, 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2020
|
(in thousands)
|
|
30-59
Days
Past Due
|
|
60-89
Days
Past Due
|
|
90 Days
or More
Past Due
|
|
Total
Past Due
|
|
Current
|
|
Total
Loans
|
|
Non-
accrual
Loans
|
|
Total Loans
90 Days or
More Past
Due and
Accruing
|
Commercial and industrial
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
285
|
|
|
$
|
285
|
|
|
$
|
94,942
|
|
|
$
|
95,227
|
|
|
$
|
218
|
|
|
$
|
73
|
|
Owner-occupied commercial real estate
|
|
—
|
|
|
—
|
|
|
464
|
|
|
464
|
|
|
74,273
|
|
|
74,737
|
|
|
464
|
|
|
—
|
|
Investor commercial real estate
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
13,421
|
|
|
13,421
|
|
|
—
|
|
|
—
|
|
Construction
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
64,581
|
|
|
64,581
|
|
|
—
|
|
|
—
|
|
Single tenant lease financing
|
|
—
|
|
|
—
|
|
|
4,680
|
|
|
4,680
|
|
|
967,595
|
|
|
972,275
|
|
|
4,680
|
|
|
—
|
|
Public finance
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
627,678
|
|
|
627,678
|
|
|
—
|
|
|
—
|
|
Healthcare finance
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
372,266
|
|
|
372,266
|
|
|
—
|
|
|
—
|
|
Small business lending
|
|
676
|
|
|
43
|
|
|
926
|
|
|
1,645
|
|
|
65,630
|
|
|
67,275
|
|
|
926
|
|
|
—
|
|
Residential mortgage
|
|
870
|
|
|
—
|
|
|
1,042
|
|
|
1,912
|
|
|
216,818
|
|
|
218,730
|
|
|
991
|
|
|
51
|
|
Home equity
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
23,855
|
|
|
23,855
|
|
|
—
|
|
|
—
|
|
Other consumer
|
|
95
|
|
|
149
|
|
|
1
|
|
|
245
|
|
|
296,360
|
|
|
296,605
|
|
|
39
|
|
|
1
|
|
Total
|
|
$
|
1,641
|
|
|
$
|
192
|
|
|
$
|
7,398
|
|
|
$
|
9,231
|
|
|
$
|
2,817,419
|
|
|
$
|
2,826,650
|
|
|
$
|
7,318
|
|
|
$
|
125
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2019
|
(in thousands)
|
|
30-59
Days
Past Due
|
|
60-89
Days
Past Due
|
|
90 Days
or More
Past Due
|
|
Total
Past Due
|
|
Current
|
|
Total
Loans
|
|
Non-
accrual
Loans
|
|
Total Loans
90 Days or
More Past
Due and
Accruing
|
Commercial and industrial
|
|
$
|
15
|
|
|
$
|
96
|
|
|
$
|
122
|
|
|
$
|
233
|
|
|
$
|
96,187
|
|
|
$
|
96,420
|
|
|
$
|
226
|
|
|
$
|
—
|
|
Owner-occupied commercial real estate
|
|
—
|
|
|
—
|
|
|
464
|
|
|
464
|
|
|
72,928
|
|
|
73,392
|
|
|
464
|
|
|
—
|
|
Investor commercial real estate
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
12,567
|
|
|
12,567
|
|
|
—
|
|
|
—
|
|
Construction
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
60,274
|
|
|
60,274
|
|
|
—
|
|
|
—
|
|
Single tenant lease financing
|
|
—
|
|
|
4,680
|
|
|
—
|
|
|
4,680
|
|
|
991,199
|
|
|
995,879
|
|
|
4,680
|
|
|
—
|
|
Public finance
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
687,094
|
|
|
687,094
|
|
|
—
|
|
|
—
|
|
Healthcare finance
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
300,612
|
|
|
300,612
|
|
|
—
|
|
|
—
|
|
Small business lending
|
|
54
|
|
|
|
|
—
|
|
|
54
|
|
|
60,225
|
|
|
60,279
|
|
|
—
|
|
|
—
|
|
Residential mortgage
|
|
—
|
|
|
—
|
|
|
1,177
|
|
|
1,177
|
|
|
312,672
|
|
|
313,849
|
|
|
761
|
|
|
416
|
|
Home equity
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
24,306
|
|
|
24,306
|
|
|
—
|
|
|
—
|
|
Other consumer
|
|
240
|
|
|
107
|
|
|
—
|
|
|
347
|
|
|
294,962
|
|
|
295,309
|
|
|
33
|
|
|
—
|
|
Total
|
|
$
|
309
|
|
|
$
|
4,883
|
|
|
$
|
1,763
|
|
|
$
|
6,955
|
|
|
$
|
2,913,026
|
|
|
$
|
2,919,981
|
|
|
$
|
6,164
|
|
|
$
|
416
|
|
Impaired Loans
A loan is designated as impaired, in accordance with the impairment accounting guidance, when, based on current information or events, it is probable that the Company will be unable to collect all amounts due (principal and interest) according to the contractual terms of the loan agreement. Payments with delays generally not exceeding 90 days outstanding are not considered impaired. Certain nonaccrual and substantially all delinquent loans more than 90 days past due may be considered to be impaired. Generally, loans are placed on nonaccrual status at 90 days past due and accrued interest is reversed against earnings, unless the loan is well-secured and in the process of collection. The accrual of interest on impaired and nonaccrual loans is discontinued when, in management’s opinion, the borrower may be unable to meet payments as they become due.
Impaired loans include nonperforming loans as well as loans modified in TDRs where concessions have been granted to borrowers experiencing financial difficulties. These concessions could include a reduction in the interest rate on the loan, payment extensions, forgiveness of principal, forbearance, or other actions intended to maximize collection.
ASC Topic 310, Receivables, requires that impaired loans be measured based on the present value of expected future cash flows discounted at the loans’ effective interest rates or the fair value of the underlying collateral, less costs to sell, and allows existing methods for recognizing interest income.
The following table presents the Company’s impaired loans as of March 31, 2020 and December 31, 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2020
|
|
December 31, 2019
|
(in thousands)
|
|
Recorded
Balance
|
|
Unpaid
Principal
Balance
|
|
Specific
Allowance
|
|
Recorded
Balance
|
|
Unpaid
Principal
Balance
|
|
Specific
Allowance
|
Loans without a specific valuation allowance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial and industrial
|
|
$
|
695
|
|
|
$
|
697
|
|
|
$
|
—
|
|
|
$
|
2,693
|
|
|
$
|
2,694
|
|
|
$
|
—
|
|
Owner-occupied commercial real estate
|
|
595
|
|
|
598
|
|
|
—
|
|
|
2,325
|
|
|
2,327
|
|
|
—
|
|
Small business lending
|
|
3,327
|
|
|
3,327
|
|
|
—
|
|
|
3,338
|
|
|
3,338
|
|
|
—
|
|
Residential mortgage
|
|
1,360
|
|
|
1,450
|
|
|
—
|
|
|
1,135
|
|
|
1,209
|
|
|
—
|
|
Other consumer
|
|
48
|
|
|
116
|
|
|
—
|
|
|
43
|
|
|
107
|
|
|
—
|
|
Total
|
|
6,025
|
|
|
6,188
|
|
|
—
|
|
|
9,534
|
|
|
9,675
|
|
|
—
|
|
Loans with a specific valuation allowance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial and industrial
|
|
203
|
|
|
240
|
|
|
109
|
|
|
207
|
|
|
244
|
|
|
109
|
|
Single tenant lease financing
|
|
4,680
|
|
|
4,680
|
|
|
1,660
|
|
|
4,680
|
|
|
4,680
|
|
|
1,660
|
|
Total
|
|
4,883
|
|
|
4,920
|
|
|
1,769
|
|
|
4,887
|
|
|
4,924
|
|
|
1,769
|
|
Total impaired loans
|
|
$
|
10,908
|
|
|
$
|
11,108
|
|
|
$
|
1,769
|
|
|
$
|
14,421
|
|
|
$
|
14,599
|
|
|
$
|
1,769
|
|
The table below presents average balances and interest income recognized for impaired loans during the three months ended March 31, 2020 and 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
March 31, 2020
|
|
March 31, 2019
|
(in thousands)
|
|
Average
Balance
|
|
Interest
Income
|
|
Average
Balance
|
|
Interest
Income
|
Loans without a specific valuation allowance
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial and industrial
|
|
$
|
2,066
|
|
|
$
|
18
|
|
|
$
|
4,699
|
|
|
$
|
81
|
|
Owner-occupied commercial real estate
|
|
1,890
|
|
|
2
|
|
|
1,253
|
|
|
13
|
|
Small business lending
|
|
3,332
|
|
|
—
|
|
|
952
|
|
|
14
|
|
Residential mortgage
|
|
1,274
|
|
|
—
|
|
|
2,054
|
|
|
—
|
|
Home equity
|
|
—
|
|
|
—
|
|
|
41
|
|
|
—
|
|
Other consumer
|
|
45
|
|
|
—
|
|
|
76
|
|
|
—
|
|
Total
|
|
8,607
|
|
|
20
|
|
|
9,075
|
|
|
108
|
|
Loans with a specific valuation allowance
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial and industrial
|
|
204
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Single tenant lease financing
|
|
4,680
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Total
|
|
4,884
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Total impaired loans
|
|
$
|
13,491
|
|
|
$
|
20
|
|
|
$
|
9,075
|
|
|
$
|
108
|
|
The Company had no residential mortgage other real estate owned as of March 31, 2020 and December 31, 2019. There were no loans in the process of foreclosure at March 31, 2020 and December 31, 2019.
Troubled Debt Restructurings
The loan portfolio includes TDRs, which are loans that have been modified to grant economic concessions to borrowers who have experienced financial difficulties. These concessions typically result from loss mitigation efforts and could include reductions in the interest rate, payment extensions, forgiveness of principal, forbearance, or other actions. Certain TDRs
are classified as nonperforming at the time of restructuring and typically are returned to performing status after considering the borrower’s sustained repayment performance for a reasonable period, generally not less than six consecutive months.
When loans are modified in a TDR, any possible impairment similar to other impaired loans is evaluated based on the present value of expected future cash flows, discounted at the contractual interest rate of the original loan agreement, or using the current fair value of the collateral, less selling costs, for collateral dependent loans. If it is determined that the value of the modified loan is less than the recorded balance of the loan, impairment is recognized through a specific allowance or charge-off to the allowance. In periods subsequent to modification, all TDRs, including those that have payment defaults, are evaluated for possible impairment, and impairment is recognized through the allowance.
In the course of working with troubled borrowers, the Company may choose to restructure the contractual terms of certain loans in an effort to work out an alternative payment schedule with the borrower in order to optimize the collectability of the loan. Any loan modification is reviewed by the Company to identify whether a TDR has occurred when the Company grants a concession to the borrower that it would not otherwise consider based on economic or legal reasons related to a borrower’s financial difficulties. Terms may be modified to fit the ability of the borrower to repay in line with its current financial status or the loan may be restructured to secure additional collateral and/or guarantees to support the debt, or a combination of the two.
There were no commercial and industrial loans classified as new TDRs during the three months ended March 31, 2020 and 2019. There were no performing TDRs that had payment defaults within the twelve months following modification during the three months ended March 31, 2020 and 2019.
Non-TDR Loan Modifications due to COVID-19
The “Interagency Statement on Loan Modifications and Reporting for Financial Institutions Working with Customers Affected by the Coronavirus” was issued by our banking regulators on March 22, 2020. This guidance encourages financial institutions to work prudently with borrowers who are or may be unable to meet their contractual payment obligations due to the effects of COVID-19.
Additionally, Section 4013 of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) further provides that loan modifications due to the impact of COVID-19 that would otherwise be classified as TDRs under GAAP will not be so classified. Modifications within the scope of this relief are in effect from the period beginning March 1, 2020 until the earlier of December 31, 2020 or 60 days after the date on which the national emergency related to the COVID-19 pandemic formally terminates.
In accordance with this guidance, the Company offered modifications to borrowers who were both impacted by COVID-19 and current on all principal and interest payments. The modifications completed in the three months ended March 31, 2020 consisted of only loans in the healthcare finance portfolio with total balances of $233.5 million.
Note 5: Premises and Equipment
The following table summarizes premises and equipment at March 31, 2020 and December 31, 2019.
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
March 31,
2020
|
|
December 31,
2019
|
Land
|
|
$
|
2,500
|
|
|
$
|
2,500
|
|
Right of use leased asset
|
|
1,450
|
|
|
1,602
|
|
Building and improvements
|
|
14,291
|
|
|
10,004
|
|
Furniture and equipment
|
|
10,258
|
|
|
9,689
|
|
Less: accumulated depreciation
|
|
(9,616
|
)
|
|
(9,165
|
)
|
Total
|
|
$
|
18,883
|
|
|
$
|
14,630
|
|
During 2018, the Bank's subsidiary, SPF15, Inc., (“SPF15”) acquired several parcels of land consisting of approximately 3.3 acres located in Fishers, Indiana for approximately $10.2 million, inclusive of acquisition costs. Pursuant to a Land Acquisition Agreement with the City of Fishers, Indiana (the “City”), and its Redevelopment Commission, among others, the City agreed to reimburse SPF15 for the purchase price and other specified land acquisition costs. The Land Acquisition
Agreement was replaced by a Project Agreement in December 2018, which extended the reimbursement deadline to October 31, 2019 and made additional financial incentives available to the Company for constructing an office building and associated parking garage on the property. As contemplated under the Project Agreement, the City transferred to SPF15 two additional parcels of land consisting of approximately 0.75 acres and SPF15 transferred to the Fishers Town Hall Building Corporation and third parties a certain parcel of land consisting of approximately 1.65 acres in connection with the development of the property. On October 25, 2019, the City satisfied its reimbursement obligation, resulting in the payment of SPF15 of an aggregate of $11.1 million for purchase prices and other specified land acquisition costs.
Site demolition has been completed and construction of a multi-use development, to include the Company's future headquarters, began on October 7, 2019. Development of the site is estimated to be substantially completed by September 30, 2021.
A lease is defined as a contract, or part of a contract, that conveys the right to control the use of identified property or equipment for a period of time in exchange for consideration. On January 1, 2019, the Company adopted ASU 2016-02 - Leases (Topic 842) and elected the optional transition method, which allows the Company to not separate non-lease components from the associated lease component if certain conditions are met. In addition, the Company elected not to adjust prior comparative periods.
The Company has two operating leases that are used for general office operations with remaining lease terms of two to four years. With the adoption of ASU 2016-02, operating lease agreements are required to be recognized on the condensed consolidated balance sheets as a right-of-use asset and a corresponding lease liability.
The following table shows the components of lease expense.
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
Three Months Ended
|
|
|
March 31, 2020
|
|
March 31, 2019
|
Operating lease cost
|
|
$
|
215
|
|
|
$
|
187
|
|
The following table shows supplemental cash flow information related to leases.
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
Three Months Ended
|
|
|
March 31, 2020
|
|
March 31, 2019
|
Cash paid for amounts included in the measurement of lease liabilities:
|
|
|
|
|
Operating cash flows from operating leases
|
|
$
|
231
|
|
|
$
|
200
|
|
The following table shows the operating leases’ impact on the condensed consolidated balance sheets. The Company elected not to include short-term leases (leases with original terms of 12 months or less) or equipment leases, as those amounts are insignificant. The Company’s leases do not provide an implicit rate. The discount rate utilized to determine the present value of lease payments is the Company’s incremental borrowing rate based on the information available at the lease inception date. The incremental borrowing rate is the rate of interest the Company would have to pay to borrow on a collateralized basis over a similar term in an amount equal to the lease payments in a similar economic environment.
|
|
|
|
|
|
|
|
|
|
(dollars in thousands)
|
|
|
|
|
March 31, 2020
|
|
December 31, 2019
|
Operating lease right-of-use assets
|
|
$
|
(1,485
|
)
|
|
$
|
1,602
|
|
Operating lease liabilities
|
|
(1,485
|
)
|
|
1,602
|
|
|
|
|
|
|
Weighted-average remaining lease term (years)
|
|
|
|
|
Operating leases
|
|
2.2
|
|
|
2.4
|
|
|
|
|
|
|
Weighted-average discount rate
|
|
|
|
|
Operating leases
|
|
2.0
|
%
|
|
2.0
|
%
|
The following table shows the future minimum payments of operating leases with initial or remaining terms of one year or more as of March 31, 2020.
|
|
|
|
|
|
(in thousands)
|
|
|
Twelve months ended March 31,
|
|
|
2021
|
|
$
|
824
|
|
2022
|
|
315
|
|
2023
|
|
230
|
|
2024
|
|
58
|
|
2025
|
|
—
|
|
Thereafter
|
|
—
|
|
Total lease payments
|
|
1,427
|
|
Less: imputed interest
|
|
(39
|
)
|
Total
|
|
$
|
1,388
|
|
Note 7: Goodwill
As of March 31, 2020 and December 31, 2019, the carrying amount of goodwill was $4.7 million. There have been no changes in the carrying amount of goodwill for the three months ended March 31, 2020. Goodwill is tested for impairment on an annual basis as of August 31, or whenever events or changes in circumstances indicate the carrying amount of goodwill exceeds its implied fair value. The annual test indicated no impairment existed as of August 31, 2019.
Due to the impact of COVID-19 on the economy and the financial markets, the Company evaluated goodwill and determined no triggering event has occurred since the last goodwill impairment test was conducted.
Activity for the servicing asset and the related changes in fair value for the three months ended March 31, 2020 and 2019 are shown in the table below.
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
Three Months Ended
|
|
|
March 31, 2020
|
|
March 31, 2019
|
Beginning balance
|
|
$
|
2,481
|
|
|
$
|
—
|
|
Additions
|
|
113
|
|
|
—
|
|
Changes in fair value
|
|
(179
|
)
|
|
—
|
|
Ending balance
|
|
$
|
2,415
|
|
|
$
|
—
|
|
Loans serviced for others are not included in the condensed consolidated balance sheets. The unpaid principal balances of these loans serviced for others as of March 31, 2020 and December 31, 2019 are shown in the table below.
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
|
|
March 31, 2020
|
|
December 31, 2019
|
Loan portfolios serviced for:
|
|
|
|
|
SBA guaranteed loans
|
|
$
|
103,878
|
|
|
$
|
103,981
|
|
Total
|
|
$
|
103,878
|
|
|
$
|
103,981
|
|
Loan servicing revenue totaled $0.3 million for the three months ended March 31, 2020. There was no loan servicing revenue for the three months ended March 31, 2019. Loan servicing asset revaluation, which represents the change in fair value of the servicing asset, resulted in a $0.2 million downward valuation for the three months ended March 31, 2020.
The fair value of servicing rights is highly sensitive to changes in underlying assumptions. Though fluctuations in prepayment speeds and changes in secondary market premiums generally have the most substantial impact on the fair value of servicing rights, other influencing factors include changing economic conditions, changes to the discount rate assumption and the weighted average life of the servicing portfolio. Measurement of fair value is limited to the conditions existing and the assumptions used as of a particular point in time; however, those assumptions may change over time. Refer to Note 12 - Fair Value of Financial Instruments for further details.
Note 9: Subordinated Debt
In October 2015, the Company entered into a term loan in the principal amount of $10.0 million, evidenced by a term note due 2025 (the “2025 Note”). The 2025 Note bears a fixed interest rate of 6.4375% per year, payable quarterly, and is scheduled to mature on October 1, 2025. The 2025 Note is an unsecured subordinated obligation of the Company and may be repaid, without penalty, on any interest payment date on or after October 15, 2020. The 2025 Note is intended to qualify as Tier 2 capital under regulatory guidelines.
In September 2016, the Company issued $25.0 million aggregate principal amount of 6.0% Fixed-to-Floating Rate Subordinated Notes due 2026 (the “2026 Notes”) in a public offering. The 2026 Notes initially bear a fixed interest rate of 6.0% per year to, but excluding September 30, 2021, and thereafter a floating rate equal to the then-current three-month LIBOR rate plus 485 basis points. All interest on the 2026 Notes is payable quarterly. The 2026 Notes are scheduled to mature on September 30, 2026. The 2026 Notes are unsecured subordinated obligations of the Company and may be repaid, without penalty, on any interest payment date on or after September 30, 2021. The 2026 Notes are intended to qualify as Tier 2 capital under regulatory guidelines.
In June 2019, the Company issued $37.0 million aggregate principal amount of 6.0% Fixed-to-Floating Rate Subordinated Notes due 2029 (the “2029 Notes”) in a public offering. The 2029 Notes initially bear a fixed interest rate of 6.0% per year to, but excluding, June 30, 2024, and thereafter a floating rate equal to the then-current benchmark rate (initially three-month LIBOR rate) plus 411 basis points. All interest on the 2029 Notes is payable quarterly. The 2029 Notes are scheduled to mature on June 30, 2029. The 2029 Notes are unsecured subordinated obligations of the Company and may be repaid, without penalty, on any interest payment date on or after June 30, 2024. The 2029 Notes are intended to qualify as Tier 2 capital under regulatory guidelines.
The following table presents the principal balance and unamortized debt issuance costs for the 2025 Note, the 2026 Notes and the 2029 Notes as of March 31, 2020 and December 31, 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2020
|
|
December 31, 2019
|
(in thousands)
|
Principal
|
|
Unamortized Debt Issuance Costs
|
|
Principal
|
|
Unamortized Debt Issuance Costs
|
2025 Note
|
10,000
|
|
|
(132
|
)
|
|
10,000
|
|
|
(138
|
)
|
2026 Notes
|
25,000
|
|
|
(808
|
)
|
|
25,000
|
|
|
(839
|
)
|
2029 Notes
|
37,000
|
|
|
(1,455
|
)
|
|
37,000
|
|
|
(1,495
|
)
|
Total
|
$
|
72,000
|
|
|
$
|
(2,395
|
)
|
|
$
|
72,000
|
|
|
$
|
(2,472
|
)
|
Note 10: Benefit Plans
Employment Agreement
The Company is party to an employment agreement with its Chief Executive Officer that provides for an annual base salary and an annual bonus, if any, as determined from time to time by the Compensation Committee of our Board of Directors. The annual bonus is to be determined with reference to the achievement of annual performance objectives established by the Compensation Committee for the Chief Executive Officer and other senior officers. The agreement also provides that the Chief Executive Officer may be awarded additional compensation, benefits, or consideration as the Compensation Committee may determine.
The agreement provides for the continuation of salary and certain other benefits for a specified period of time upon termination of his employment under certain circumstances, including his resignation for “good reason” or termination by the Company without “cause” at any time or any termination of his employment for any reason within twelve months following a “change in control,” along with other specific conditions.
2013 Equity Incentive Plan
The 2013 Equity Incentive Plan (the “2013 Plan”) authorizes the issuance of 750,000 shares of the Company’s common stock in the form of equity-based awards to employees, directors, and other eligible persons. Under the terms of the 2013 Plan, the pool of shares available for issuance may be used for available types of equity awards under the 2013 Plan, which includes stock options, stock appreciation rights, restricted stock awards, stock unit awards, and other share-based awards. All employees, consultants, and advisors of the Company or any subsidiary, as well as all non-employee directors of the Company, are eligible to receive awards under the 2013 Plan.
The Company recorded $0.6 million of share-based compensation expense for the three months ended March 31, 2020, related to awards made under the 2013 Plan. The company recorded $0.5 million of share-based compensation expense for the three months ended March 31, 2019, related to awards made under the 2013 plan.
The following table summarizes the status of the 2013 Plan awards as of March 31, 2020, and activity for the three months ended March 31, 2020.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted Stock Units
|
|
Weighted-Average Grant Date Fair Value Per Share
|
|
Restricted Stock Awards
|
|
Weighted-Average Grant Date Fair Value Per Share
|
|
Deferred Stock Units
|
|
Weighted-Average Grant Date Fair Value Per Share
|
Nonvested at December 31, 2019
|
107,244
|
|
|
$
|
29.03
|
|
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
—
|
|
Granted
|
66,756
|
|
|
27.56
|
|
|
13,164
|
|
|
27.56
|
|
|
3
|
|
|
23.48
|
|
Vested
|
(48,499
|
)
|
|
30.34
|
|
|
(3,336
|
)
|
|
27.56
|
|
|
(3
|
)
|
|
23.48
|
|
Forfeited
|
—
|
|
|
—
|
|
|
(1,638
|
)
|
|
27.56
|
|
|
—
|
|
|
—
|
|
Nonvested at March 31, 2020
|
125,501
|
|
|
$
|
27.74
|
|
|
8,190
|
|
|
$
|
27.56
|
|
|
—
|
|
|
$
|
—
|
|
At March 31, 2020, the total unrecognized compensation cost related to nonvested awards was $3.6 million with a weighted-average expense recognition period of 2.1 years.
Directors Deferred Stock Plan
Until January 1, 2014, the Company had a practice of granting awards under a stock compensation plan for members of the Board of Directors (“Directors Deferred Stock Plan”). The Company reserved 180,000 shares of common stock that could have been issued pursuant to the Directors Deferred Stock Plan. The Directors Deferred Stock Plan provided directors the option to elect to receive up to 100% of their annual retainer in either common stock or deferred stock rights. Deferred stock rights were to be settled in common stock following the end of the deferral period payable on the basis of one share of common stock for each deferred stock right.
The following table summarizes the status of deferred stock rights related to the Directors Deferred Stock Plan for the three months ended March 31, 2020.
|
|
|
|
|
|
|
Deferred Stock Rights
|
Outstanding, beginning of period
|
|
84,505
|
|
Granted
|
|
214
|
|
Exercised
|
|
—
|
|
Outstanding, end of period
|
|
84,719
|
|
All deferred stock rights granted during the 2020 period were additional rights issued in lieu of cash dividends payable on outstanding deferred stock rights.
Note 11: Commitments and Credit Risk
In the normal course of business, the Company makes various commitments to extend credit which are not reflected in the accompanying consolidated financial statements. At March 31, 2020 and December 31, 2019, the Company had outstanding loan commitments totaling approximately $295.9 million and $254.4 million, respectively.
In addition, the Company is a limited partner in a Small Business Investment Company fund (the “SBIC Fund”). As of March 31, 2020, the Company has committed to contribute up to $1.7 million of capital to the SBIC Fund.
Capital Commitments
Capital expenditures contracted to at the balance sheet date but not yet recognized in the financial statements are associated with the construction of premises intended to house our future corporate headquarters. The Company has entered into construction-related contracts in the amount of $65.1 million. As of March 31, 2020, $58.9 million of such contract commitments had not yet been incurred. These commitments are due within two years.
Note 12: Fair Value of Financial Instruments
ASC Topic 820, Fair Value Measurement, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 also specifies a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:
|
|
Level 1
|
Quoted prices in active markets for identical assets or liabilities
|
|
|
Level 2
|
Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities
|
|
|
Level 3
|
Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities
|
Following is a description of the valuation methodologies and inputs used for assets measured at fair value on a recurring basis and recognized in the accompanying condensed consolidated balance sheets, as well as the general classification of such assets pursuant to the valuation hierarchy.
Available-for-Sale Securities
Where quoted market prices are available in an active market, securities are classified within Level 1 of the valuation hierarchy. Level 1 securities include highly liquid mutual funds. If quoted market prices are not available, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows.
Level 2 securities include U.S. Government-sponsored agencies, municipal securities, mortgage and asset-backed securities and certain corporate securities. Matrix pricing is a mathematical technique widely used in the banking industry to value investment securities without relying exclusively on quoted prices for specific investment securities but also on the investment securities’ relationship to other benchmark quoted investment securities.
In certain cases where Level 1 or Level 2 inputs are not available, securities are classified within Level 3 of the hierarchy. Fair values are calculated using discounted cash flows. Discounted cash flows are calculated based off of the anticipated future cash flows updated to incorporate loss severities. Rating agency and industry research reports as well as default and deferral activity are reviewed and incorporated into the calculation. The Company did not own any securities classified within Level 3 of the hierarchy as of March 31, 2020 or December 31, 2019.
Loans Held-for-Sale (mandatory pricing agreements)
The fair value of loans held-for-sale is determined using quoted prices for similar assets, adjusted for specific attributes of that loan (Level 2).
Servicing Asset
Fair value is based on a loan-by-loan basis taking into consideration the original maturity of the loans, the current age of the loans and the remaining term to maturity. The valuation methodology utilized for the servicing assets begins with generating estimated future cash flows for each servicing asset, based on their unique characteristics and market-based assumptions for prepayment speeds and costs to service. The present value of the future cash flows is then calculated utilizing market-based discount rate assumptions (Level 3).
Interest Rate Swap Agreements
The fair value of interest rate swap agreements is estimated using current market interest rates as of the balance sheet date and calculated using discounted cash flows that are observable or that can be corroborated by observable market data and, therefore, are classified within Level 2 of the valuation hierarchy.
Forward Contracts
The fair values of forward contracts on to-be-announced securities are determined using quoted prices in active markets or benchmarked thereto (Level 1).
Interest Rate Lock Commitments
The fair values of interest rate lock commitments (“IRLCs”) are determined using the projected sale price of individual loans based on changes in market interest rates, projected pull-through rates (the probability that an IRLC will ultimately result in an originated loan), the reduction in the value of the applicant’s option due to the passage of time, and the remaining origination costs to be incurred based on management’s estimate of market costs (Level 3).
The following tables present the fair value measurements of assets and liabilities recognized in the accompanying condensed consolidated balance sheets measured at fair value on a recurring basis and the level within the fair value hierarchy in which the fair value measurements fall at March 31, 2020 and December 31, 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2020 Fair Value Measurements Using
|
(in thousands)
|
|
Fair
Value
|
|
Quoted Prices
in Active Markets for Identical Assets
(Level 1)
|
|
Significant
Other
Observable
Inputs
(Level 2)
|
|
Significant
Unobservable
Inputs
(Level 3)
|
U.S. Government-sponsored agencies
|
|
$
|
70,004
|
|
|
$
|
—
|
|
|
$
|
70,004
|
|
|
$
|
—
|
|
Municipal securities
|
|
94,819
|
|
|
—
|
|
|
94,819
|
|
|
—
|
|
Agency mortgage-backed securities
|
|
282,632
|
|
|
—
|
|
|
282,632
|
|
|
—
|
|
Private label mortgage-backed securities
|
|
115,024
|
|
|
|
|
115,024
|
|
|
—
|
|
Asset-backed securities
|
|
4,713
|
|
|
—
|
|
|
4,713
|
|
|
—
|
|
Corporate securities
|
|
41,490
|
|
|
—
|
|
|
41,490
|
|
|
—
|
|
Total available-for-sale securities
|
|
608,682
|
|
|
—
|
|
|
608,682
|
|
|
—
|
|
Servicing asset
|
|
2,415
|
|
|
—
|
|
|
—
|
|
|
2,415
|
|
Interest rate swap liabilities
|
|
(78,552
|
)
|
|
—
|
|
|
(78,552
|
)
|
|
—
|
|
Loans held-for-sale (mandatory pricing agreements)
|
|
52,394
|
|
|
—
|
|
|
52,394
|
|
|
—
|
|
Forward contracts
|
|
(2,298
|
)
|
|
(2,298
|
)
|
|
—
|
|
|
—
|
|
IRLCs
|
|
2,064
|
|
|
—
|
|
|
—
|
|
|
2,064
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2019
Fair Value Measurements Using
|
(in thousands)
|
|
Fair
Value
|
|
Quoted Prices
in Active Markets for Identical Assets
(Level 1)
|
|
Significant
Other
Observable
Inputs
(Level 2)
|
|
Significant
Unobservable
Inputs
(Level 3)
|
U.S. Government-sponsored agencies
|
|
$
|
75,872
|
|
|
$
|
—
|
|
|
$
|
75,872
|
|
|
$
|
—
|
|
Municipal securities
|
|
97,652
|
|
|
—
|
|
|
97,652
|
|
|
—
|
|
Agency mortgage-backed securities
|
|
261,440
|
|
|
—
|
|
|
261,440
|
|
|
—
|
|
Private label mortgage-backed securities
|
|
63,613
|
|
|
—
|
|
|
63,613
|
|
|
—
|
|
Asset-backed securities
|
|
4,955
|
|
|
—
|
|
|
4,955
|
|
|
—
|
|
Corporate securities
|
|
37,320
|
|
|
—
|
|
|
37,320
|
|
|
—
|
|
Total available-for-sale securities
|
|
540,852
|
|
|
—
|
|
|
540,852
|
|
|
—
|
|
Servicing asset
|
|
2,481
|
|
|
—
|
|
|
—
|
|
|
2,481
|
|
Interest rate swap liabilities
|
|
(37,786
|
)
|
|
—
|
|
|
(37,786
|
)
|
|
—
|
|
Loans held-for-sale (mandatory pricing agreements)
|
|
56,097
|
|
|
—
|
|
|
56,097
|
|
|
—
|
|
Forward contracts
|
|
(153
|
)
|
|
(153
|
)
|
|
—
|
|
|
—
|
|
IRLCs
|
|
910
|
|
|
—
|
|
|
—
|
|
|
910
|
|
The following tables reconcile the beginning and ending balances of recurring fair value measurements recognized in the accompanying condensed consolidated balance sheets using significant unobservable (Level 3) inputs for the three months ended March 31, 2020 and 2019.
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
(in thousands)
|
|
Servicing Asset
|
|
Interest Rate Lock
Commitments
|
Balance, January 1, 2020
|
|
$
|
2,481
|
|
|
$
|
910
|
|
Total realized (losses) gains
|
|
|
|
|
|
Additions
|
|
113
|
|
|
—
|
|
Change in fair value
|
|
(179
|
)
|
|
1,154
|
|
Balance, March 31, 2020
|
|
2,415
|
|
|
2,064
|
|
|
|
|
|
|
Balance as of January 1, 2019
|
|
$
|
—
|
|
|
$
|
389
|
|
Total realized gains
|
|
|
|
|
Change in fair value
|
|
—
|
|
|
392
|
|
Balance, March 31, 2019
|
|
$
|
—
|
|
|
$
|
781
|
|
The following describes the valuation methodologies and inputs used for assets measured at fair value on a nonrecurring basis, as well as the general classification of such assets pursuant to the valuation hierarchy.
Impaired Loans (Collateral Dependent)
Loans for which it is probable that the Company will not collect all principal and interest due according to contractual terms are measured for impairment. The amount of impairment may be determined based on the fair value of the underlying collateral, less costs to sell, the estimated present value of future cash flows or the loan’s observable market price.
If the impaired loan is identified as collateral dependent, the fair value of the underlying collateral, less costs to sell, is used to measure impairment. This method requires obtaining a current independent appraisal of the collateral and applying a discount factor to the value. If the impaired loan is not collateral dependent, the Company utilizes a discounted cash flow analysis to measure impairment.
Impaired loans with a specific valuation allowance based on the value of the underlying collateral or a discounted cash flow analysis are classified as Level 3 assets.
The following table presents the fair value measurements of assets and liabilities recognized in the accompanying condensed consolidated balance sheets measured at fair value on a nonrecurring basis and the level within the fair value hierarchy in which the fair value measurement falls at March 31, 2020 and December 31, 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2019
|
(in thousands)
|
|
|
|
Fair Value Measurements Using
|
|
|
Fair
Value
|
|
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
|
|
Significant
Other
Observable
Inputs
(Level 2)
|
|
Significant
Unobservable
Inputs
(Level 3)
|
Impaired loans
|
|
$
|
3,019
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
3,019
|
|
Significant Unobservable (Level 3) Inputs
The following tables present quantitative information about unobservable inputs used in recurring and nonrecurring Level 3 fair value measurements.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(dollars in thousands)
|
|
Fair Value at
March 31, 2020
|
|
Valuation
Technique
|
|
Significant Unobservable
Inputs
|
|
Range
|
|
Weighted-Average Range
|
IRLCs
|
|
$
|
2,064
|
|
|
Discounted cash flow
|
|
Loan closing rates
|
|
36% - 100%
|
|
56%
|
Servicing asset
|
|
2,415
|
|
|
Discounted cash flow
|
|
Prepayment speeds
|
|
0% - 25%
|
|
14.4%
|
|
|
|
|
|
|
Expected weighted-average loan life
|
|
3.3 - 5.3 years
|
|
4.7 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(dollars in thousands)
|
|
Fair Value at
December 31, 2019
|
|
Valuation
Technique
|
|
Significant Unobservable
Inputs
|
|
Range
|
|
Weighted-Average Range
|
Impaired loans
|
|
$
|
3,019
|
|
|
Fair value of collateral
|
|
Discount for type of property and current market conditions
|
|
10%
|
|
10%
|
IRLCs
|
|
910
|
|
|
Discounted cash flow
|
|
Loan closing rates
|
|
50% - 100%
|
|
84%
|
Servicing asset
|
|
2,481
|
|
|
Discounted cash flow
|
|
Prepayment speeds
|
|
0% - 25%
|
|
13.5%
|
|
|
|
|
|
|
Expected weighted-average loan life
|
|
3.2 - 5.7 years
|
|
5.0 years
|
The following methods were used to estimate the fair value of all other financial instruments recognized in the accompanying condensed consolidated balance sheets at amounts other than fair value.
Cash and Cash Equivalents
For these instruments, the carrying amount is a reasonable estimate of fair value.
Securities Held-to-Maturity
Fair values are determined by using models that are based on security-specific details, as well as relevant industry and economic factors. The most significant of these inputs are quoted market prices and interest rate spreads on relevant benchmark securities.
Loans Held-for-Sale (best efforts pricing agreements)
The fair value of these loans approximates carrying value.
Loans
The fair value of loans is estimated on an exit price basis incorporating discounts for credit, liquidity and marketability factors.
Accrued Interest Receivable
The fair value of these financial instruments approximates carrying value.
Federal Home Loan Bank of Indianapolis Stock
The fair value approximates carrying value.
Deposits
The fair value of noninterest-bearing and interest-bearing demand deposits, savings and money market accounts approximates carrying value. The fair value of fixed maturity certificates of deposit and brokered deposits are estimated using rates currently offered for deposits of similar remaining maturities.
Advances from Federal Home Loan Bank
The fair value of fixed rate advances is estimated using rates currently available for advances with similar remaining maturities. The carrying value of variable rate advances approximates fair value.
Subordinated Debt
The fair value of the Company’s publicly traded subordinated debt is obtained from quoted market prices. The fair value of the Company’s remaining subordinated debt is estimated using discounted cash flow analysis, based on current borrowing rates for similar types of debt instruments.
Accrued Interest Payable
The fair value of these financial instruments approximates carrying value.
Commitments
The fair value of commitments to extend credit are based on fees currently charged to enter into similar agreements with similar maturities and interest rates. The Company determined that the fair value of commitments was zero based on the contractual value of outstanding commitments at each of March 31, 2020 and December 31, 2019.
The following tables present the carrying value and estimated fair value of all financial assets and liabilities at March 31, 2020 and December 31, 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2020
Fair Value Measurements Using
|
(in thousands)
|
|
Carrying
Amount
|
|
Fair Value
|
|
Quoted Prices
In Active
Market for
Identical Assets
(Level 1)
|
|
Significant
Other
Observable
Inputs
(Level 2)
|
|
Significant
Unobservable
Inputs
(Level 3)
|
Cash and cash equivalents
|
|
$
|
351,268
|
|
|
$
|
351,268
|
|
|
$
|
351,268
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Securities held-to-maturity
|
|
66,331
|
|
|
69,468
|
|
|
—
|
|
|
69,468
|
|
|
—
|
|
Net loans
|
|
2,869,236
|
|
|
2,842,894
|
|
|
—
|
|
|
—
|
|
|
2,842,894
|
|
Accrued interest receivable
|
|
16,960
|
|
|
16,960
|
|
|
16,960
|
|
|
—
|
|
|
—
|
|
Federal Home Loan Bank of Indianapolis stock
|
|
25,650
|
|
|
25,650
|
|
|
—
|
|
|
25,650
|
|
|
—
|
|
Deposits
|
|
3,178,506
|
|
|
3,245,748
|
|
|
1,156,978
|
|
|
—
|
|
|
2,088,770
|
|
Advances from Federal Home Loan Bank
|
|
514,911
|
|
|
546,378
|
|
|
—
|
|
|
546,378
|
|
|
—
|
|
Subordinated debt
|
|
69,605
|
|
|
61,092
|
|
|
50,890
|
|
|
10,202
|
|
|
—
|
|
Accrued interest payable
|
|
3,293
|
|
|
3,293
|
|
|
3,293
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2019
Fair Value Measurements Using
|
(in thousands)
|
|
Carrying
Amount
|
|
Fair Value
|
|
Quoted Prices
In Active
Market for
Identical
Assets
(Level 1)
|
|
Significant
Other
Observable
Inputs
(Level 2)
|
|
Significant
Unobservable
Inputs
(Level 3)
|
Cash and cash equivalents
|
|
$
|
327,361
|
|
|
$
|
327,361
|
|
|
$
|
327,361
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Securities held-to-maturity
|
|
61,878
|
|
|
62,560
|
|
|
—
|
|
|
62,560
|
|
|
—
|
|
Net loans
|
|
2,941,707
|
|
|
2,876,688
|
|
|
—
|
|
|
—
|
|
|
2,876,688
|
|
Accrued interest receivable
|
|
18,607
|
|
|
18,607
|
|
|
18,607
|
|
|
—
|
|
|
—
|
|
Federal Home Loan Bank of Indianapolis stock
|
|
25,650
|
|
|
25,650
|
|
|
—
|
|
|
25,650
|
|
|
—
|
|
Deposits
|
|
3,153,963
|
|
|
3,232,065
|
|
|
1,002,141
|
|
|
—
|
|
|
2,229,924
|
|
Advances from Federal Home Loan Bank
|
|
514,910
|
|
|
520,950
|
|
|
—
|
|
|
520,950
|
|
|
—
|
|
Subordinated debt
|
|
69,528
|
|
|
75,206
|
|
|
64,996
|
|
|
10,210
|
|
|
—
|
|
Accrued interest payable
|
|
3,767
|
|
|
3,767
|
|
|
3,767
|
|
|
—
|
|
|
—
|
|
Note 13: Mortgage Banking Activities
The Company’s residential real estate lending business originates mortgage loans for customers and typically sells a majority of the originated loans into the secondary market. For most of the mortgages it sells in the secondary market, the Company hedges its mortgage banking pipeline by entering into forward contracts for the future delivery of mortgage loans to third party investors and entering into IRLCs with potential borrowers to fund specific mortgage loans that will be sold into the secondary market. To facilitate the hedging of the loans, the Company has elected the fair value option for loans originated and intended for sale in the secondary market under mandatory pricing agreements. Changes in the fair value of loans held-for-sale, IRLCs and forward contracts are recorded in the mortgage banking activities line item within noninterest income. Refer to Note 14 for further information on derivative financial instruments.
During the three months ended March 31, 2020 and 2019, the Company originated mortgage loans held-for-sale of $215.4 million and $75.2 million, respectively, and sold $225.5 million and $81.0 million of mortgage loans, respectively, into the secondary market. Additionally, the Company sold $90.8 million of portfolio residential mortgage loans during the three months ended March 31, 2020 and sold $5.2 million of portfolio residential mortgage loans during the three months ended March 31, 2019.
The following table presents the components of income from mortgage banking activities for the three months ended March 31, 2020 and 2019.
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31,
|
(in thousands)
|
2020
|
|
2019
|
Gain on loans sold
|
$
|
4,343
|
|
|
$
|
1,473
|
|
Gain (loss) resulting from the change in fair value of loans held-for-sale
|
316
|
|
|
(182
|
)
|
(Loss) gain resulting from the change in fair value of derivatives
|
(991
|
)
|
|
326
|
|
Net revenue from mortgage banking activities
|
$
|
3,668
|
|
|
$
|
1,617
|
|
Fluctuations in interest rates and changes in IRLC and loan volume within the mortgage banking pipeline may cause volatility in the fair value of loans held-for-sale and the fair value of derivatives used to hedge the mortgage banking pipeline.
Note 14: Derivative Financial Instruments
The Company uses derivative financial instruments to help manage exposure to interest rate risk and the effects that changes in interest rates may have on net income and the fair value of assets and liabilities. The Company enters into interest rate swap agreements as part of its asset/liability management strategy to help manage its interest rate risk position. Additionally, the Company enters into forward contracts for the future delivery of mortgage loans to third-party investors and enters into IRLCs with potential borrowers to fund specific mortgage loans that will be sold into the secondary market. The forward contracts are entered into in order to economically hedge the effect of changes in interest rates resulting from the Company’s commitment to fund the loans.
The Company entered into various interest rate swap agreements designated and qualifying as accounting hedges during the reported periods. Designating an interest rate swap as an accounting hedge allows the Company to recognize gains and losses, less any ineffectiveness, in the condensed consolidated statements of income within the same period that the hedged item affects earnings. The Company includes the gain or loss on the hedged items in the same line item as the offsetting loss or gain on the related interest rate swaps. For derivative instruments that are designated and qualify as cash flow hedges, any gains or losses related to changes in fair value are recorded in accumulated other comprehensive loss, net of tax. The fair value of interest rate swaps with a positive fair value are reported in accrued income and other assets in the condensed consolidated balance sheets, while interest rate swaps with a negative fair value are reported in accrued expenses and other liabilities in the condensed consolidated balance sheets.
The IRLCs and forward contracts are not designated as accounting hedges and are recorded at fair value with changes in fair value reflected in noninterest income on the condensed consolidated statements of income. The fair value of derivative instruments with a positive fair value are reported in accrued income and other assets in the condensed consolidated balance sheets, while derivative instruments with a negative fair value are reported in accrued expenses and other liabilities in the condensed consolidated balance sheets.
The following table presents amounts that were recorded on the condensed consolidated balance sheets related to cumulative basis adjustments for interest rate swap derivatives designated as fair value accounting hedges as of March 31, 2020 and December 31, 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
Carrying amount of the hedged asset
|
|
Cumulative amount of fair value hedging adjustment included in the carrying amount of the hedged assets
|
Line item in the condensed consolidated balance sheets in which the hedged item is included
|
|
March 31, 2020
|
|
December 31, 2019
|
|
March 31, 2020
|
|
December 31, 2019
|
Loans
|
|
$
|
494,019
|
|
|
$
|
474,957
|
|
|
$
|
44,586
|
|
|
$
|
21,440
|
|
Securities available-for-sale (1)
|
|
152,551
|
|
|
151,538
|
|
|
6,790
|
|
|
2,802
|
|
(1) These amounts include the amortized cost basis of closed portfolios used to designate hedging relationships in which the hedged item
is the last layer expected to be remaining at the end of the hedging relationship. At both March 31, 2020 and December 31, 2019, the amounts of the designated hedged items were $88.2 million.
The following tables present a summary of interest rate swap derivatives designated as fair value accounting hedges of fixed-rate receivables used in the Company’s asset/liability management activities at March 31, 2020 and December 31, 2019, identified by the underlying interest rate-sensitive instruments.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(dollars in thousands)
March 31, 2020
|
|
Notional
|
|
Weighted- Average Remaining Maturity
|
|
|
|
Weighted-Average Ratio
|
Instruments Associated With
|
|
Value
|
|
(years)
|
|
Fair Value
|
|
Receive
|
|
Pay
|
Loans
|
|
$
|
424,834
|
|
|
5.3
|
|
$
|
(44,872
|
)
|
|
3-month LIBOR
|
|
2.86
|
%
|
Securities available-for-sale
|
|
88,200
|
|
|
3.9
|
|
(6,793
|
)
|
|
3-month LIBOR
|
|
2.54
|
%
|
Total at March 31, 2020
|
|
$
|
513,034
|
|
|
5.0
|
|
$
|
(51,665
|
)
|
|
3-month LIBOR
|
|
2.80
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(dollars in thousands)
December 31, 2019
|
|
Notional
|
|
Weighted- Average Remaining Maturity
|
|
|
|
Weighted-Average Ratio
|
Instruments Associated With
|
|
Value
|
|
(years)
|
|
Fair Value
|
|
Receive
|
|
Pay
|
Loans
|
|
$
|
427,446
|
|
|
5.5
|
|
$
|
(21,551
|
)
|
|
3-month LIBOR
|
|
2.86
|
%
|
Securities available-for-sale
|
|
88,200
|
|
|
4.1
|
|
(2,806
|
)
|
|
3-month LIBOR
|
|
2.54
|
%
|
Total at December 31, 2019
|
|
$
|
515,646
|
|
|
5.3
|
|
$
|
(24,357
|
)
|
|
3-month LIBOR
|
|
2.80
|
%
|
The following tables present a summary of interest rate swap derivatives designated as cash flow accounting hedges of variable-rate liabilities used in the Company’s asset/liability management activities at March 31, 2020 and December 31, 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(dollars in thousands)
March 31, 2020
|
|
Notional
|
|
Weighted- Average Remaining Maturity
|
|
|
|
Weighted-Average Ratio
|
Cash Flow Hedges
|
|
Value
|
|
(years)
|
|
Fair Value
|
|
Receive
|
|
Pay
|
Interest rate swaps
|
|
$
|
110,000
|
|
|
6.8
|
|
$
|
(17,509
|
)
|
|
3-month LIBOR
|
|
2.88
|
%
|
Interest rate swaps
|
|
100,000
|
|
|
3.7
|
|
(9,378
|
)
|
|
1-month LIBOR
|
|
2.88
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(dollars in thousands)
December 31, 2019
|
|
Notional
|
|
Weighted- Average Remaining Maturity
|
|
|
|
Weighted-Average Ratio
|
Cash Flow Hedges
|
|
Value
|
|
(years)
|
|
Fair Value
|
|
Receive
|
|
Pay
|
Interest rate swaps
|
|
$
|
110,000
|
|
|
7.1
|
|
$
|
(8,390
|
)
|
|
3-month LIBOR
|
|
2.88
|
%
|
Interest rate swaps
|
|
100,000
|
|
|
4.0
|
|
(5,040
|
)
|
|
1-month LIBOR
|
|
2.88
|
%
|
These derivative financial instruments were entered into for the purpose of managing the interest rate risk of certain assets and liabilities. The Company pledged $81.3 million and $42.3 million of cash collateral to counterparties as security for its obligations related to these interest rate swap transactions at March 31, 2020 and December 31, 2019, respectively. Collateral posted and received is dependent on the market valuation of the underlying hedges.
The following table presents the notional amount and fair value of interest rate swaps, IRLCs and forward contracts utilized by the Company at March 31, 2020 and December 31, 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2020
|
|
December 31, 2019
|
(in thousands)
|
|
Notional
Amount
|
|
Fair
Value
|
|
Notional
Amount
|
|
Fair
Value
|
Asset Derivatives
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivatives designated as hedging instruments
|
|
|
|
|
|
|
|
|
Interest rate swaps associated with loans
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Interest rate swaps associated with securities available-for-sale
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Derivatives not designated as hedging instruments
|
|
|
|
|
|
|
|
|
|
|
|
|
IRLCs
|
|
139,907
|
|
|
2,064
|
|
|
56,256
|
|
|
910
|
|
Total contracts
|
|
$
|
139,907
|
|
|
$
|
2,064
|
|
|
$
|
56,256
|
|
|
$
|
910
|
|
Liability Derivatives
|
|
|
|
|
|
|
|
|
Derivatives designated as hedging instruments
|
|
|
|
|
|
|
|
|
Interest rate swaps associated with loans
|
|
$
|
424,834
|
|
|
$
|
(44,872
|
)
|
|
$
|
427,446
|
|
|
$
|
(21,551
|
)
|
Interest rate swaps associated with securities available-for-sale
|
|
88,200
|
|
|
(6,793
|
)
|
|
88,200
|
|
|
(2,806
|
)
|
Interest rate swaps associated with liabilities
|
|
210,000
|
|
|
(26,887
|
)
|
|
210,000
|
|
|
(13,429
|
)
|
Derivatives not designated as hedging instruments
|
|
|
|
|
|
|
|
|
Forward contracts
|
|
106,750
|
|
|
(2,298
|
)
|
|
115,000
|
|
|
(153
|
)
|
Total contracts
|
|
$
|
829,784
|
|
|
$
|
(80,850
|
)
|
|
$
|
840,646
|
|
|
$
|
(37,939
|
)
|
The fair value of interest rate swaps was estimated using a discounted cash flow method that incorporates current market interest rates as of the balance sheet date. Fair values of IRLCs and forward contracts were estimated using changes in mortgage interest rates from the date the Company entered into the IRLC and the balance sheet date.
The following table presents the effects of the Company’s cash flow hedge relationships on the condensed consolidated statements of comprehensive income during the three months ended March 31, 2020 and 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount of Loss Recognized in Other Comprehensive (Loss) Income in The Three Months Ended
|
(in thousands)
|
|
March 31, 2020
|
|
March 31, 2019
|
Interest rate swap agreements
|
|
$
|
(13,458
|
)
|
|
$
|
(3,572
|
)
|
The following table summarizes the periodic changes in the fair value of derivatives not designated as hedging instruments on the condensed consolidated statements of income for the three months ended March 31, 2020 and 2019.
|
|
|
|
|
|
|
|
|
|
|
|
Amount of Gain / (Loss) Recognized in the Three Months Ended
|
(in thousands)
|
|
March 31, 2020
|
|
March 31, 2019
|
Asset Derivatives
|
|
|
|
|
|
|
Derivatives not designated as hedging instruments
|
|
|
|
|
|
|
IRLCs
|
|
$
|
1,154
|
|
|
$
|
392
|
|
|
|
|
|
|
Liability Derivatives
|
|
|
|
|
|
|
Derivatives not designated as hedging instruments
|
|
|
|
|
Forward contracts
|
|
$
|
(2,145
|
)
|
|
$
|
(67
|
)
|
The following table presents the effects of the Company’s interest rate swap agreements on the condensed consolidated statements of income during the three months ended March 31, 2020 and 2019.
|
|
|
|
|
|
|
|
|
|
(in thousands)
Line item in the condensed consolidated statements of income
|
|
Three Months Ended
|
|
March 31, 2020
|
|
March 31, 2019
|
Interest income
|
|
|
|
|
Loans
|
|
$
|
(1,224
|
)
|
|
$
|
21
|
|
Securities - taxable
|
|
(91
|
)
|
|
(7
|
)
|
Securities - non-taxable
|
|
(67
|
)
|
|
45
|
|
Total interest income
|
|
(1,382
|
)
|
|
59
|
|
Interest expense
|
|
|
|
|
|
|
Deposits
|
|
307
|
|
|
90
|
|
Other borrowed funds
|
|
322
|
|
|
34
|
|
Total interest expense
|
|
629
|
|
|
124
|
|
Net interest income
|
|
$
|
(2,011
|
)
|
|
$
|
(65
|
)
|
Note 15: Accumulated Other Comprehensive Loss
The components of accumulated other comprehensive loss, included in stockholders' equity, are presented in the table below.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
Available-For-Sale Securities
|
|
Cash Flow Hedges
|
|
Total
|
Balance, January 1, 2020
|
|
$
|
(4,388
|
)
|
|
$
|
(9,803
|
)
|
|
$
|
(14,191
|
)
|
Net change in unrealized gain (loss)
|
|
6,299
|
|
|
(13,458
|
)
|
|
(7,159
|
)
|
Reclassification of gain realized and included in earnings
|
|
(41
|
)
|
|
—
|
|
|
(41
|
)
|
Accumulated other comprehensive income (loss) before income tax
|
|
1,870
|
|
|
(23,261
|
)
|
|
(21,391
|
)
|
Income tax provision (benefit)
|
|
2,109
|
|
|
(3,634
|
)
|
|
(1,525
|
)
|
Balance, March 31, 2020
|
|
$
|
(239
|
)
|
|
$
|
(19,627
|
)
|
|
$
|
(19,866
|
)
|
|
|
|
|
|
|
|
Balance, January 1, 2019
|
|
$
|
(13,360
|
)
|
|
$
|
(3,181
|
)
|
|
$
|
(16,541
|
)
|
Net change in unrealized gain (loss)
|
|
6,910
|
|
|
(3,572
|
)
|
|
3,338
|
|
Accumulated other comprehensive loss before income tax
|
|
(6,450
|
)
|
|
(6,753
|
)
|
|
(13,203
|
)
|
Income tax provision (benefit)
|
|
1,930
|
|
|
(965
|
)
|
|
965
|
|
Balance, March 31, 2019
|
|
$
|
(8,380
|
)
|
|
$
|
(5,788
|
)
|
|
$
|
(14,168
|
)
|
Note 16: Recent Accounting Pronouncements
ASU 2016-13 - Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (June 2016)
The main objective of this update is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates.
The amendments affect entities holding financial assets that are not accounted for at fair value through net income. The amendments affect loans, debt securities, off-balance-sheet credit exposures, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in this update affect an entity to varying degrees depending on the credit quality of the assets held by the entity, their duration, and how the entity applies current GAAP. There is diversity in practice in applying the incurred loss methodology, which means that before transition some entities may be more aligned under current GAAP than others to the new measure of expected credit losses. The following describes the main provisions of this update.
•Assets Measured at Amortized Cost: The amendments in this update require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The statements of income reflect the measurement of credit losses for newly recognized financial assets, as well as the expected increase or decrease of credit losses that have taken place during the period. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances.
•Available-for-Sale Debt Securities: Credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. Available-for-sale accounting recognizes that value may be realized either through collection of contractual cash flows or through sale of the security. Therefore, the amendments limit the amount of the allowance for credit losses to the amount by which fair value is below amortized cost because the classification as available-for-sale is premised on an investment strategy
that recognizes that the investment could be sold at fair value if cash collection would result in the realization of an amount less than fair value.
•In May 2019, the FASB issued ASU 2019-05 - Financial Instruments - Credit Losses (Topic 326) - Targeted Transition Relief. This ASU allows an option for preparers to irrevocably elect the fair value option, on an instrument-by-instrument basis, for eligible financial assets measured at amortized cost basis upon adoption of the credit losses standard. This increases the comparability of financial statement information provided by institutions that otherwise would have reported similar financial instruments using different measurement methodologies, potentially decreasing costs for financial statement preparers while providing more useful information to investors and other users.
For public business entities that are SEC filers, the amendments in this update are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All entities may early adopt the amendments in this update as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. In October 2019, the FASB voted to delay the effective date for smaller reporting companies to fiscal years beginning after December 15, 2022. An entity will apply the amendments in this update through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (that is, a modified-retrospective approach). A prospective transition approach is required for debt securities for which an OTTI had been recognized before the effective date. The effect of a prospective transition approach is to maintain the same amortized cost basis before and after the effective date of this update.
The Company does not expect to early adopt and is currently evaluating the impact of the amendments on the Company’s condensed consolidated financial statements. The Company currently cannot determine or reasonably quantify the impact of the adoption of the amendments due to the complexity and extensive changes. The Company intends to develop processes and procedures prior to the effective date to ensure it is fully compliant with the amendments at the adoption date. The Company has formed an implementation committee and has engaged a third-party consultant to assist in developing current expected credit losses (“CECL”) models using appropriate methodologies.
ASU 2018-13 - Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (August 2018)
The amendments in this update modify the disclosure requirements on fair value measurements in ASC Topic 820. This ASU eliminates the requirements to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels and the valuation processes for Level 3 fair value measurements. In addition, this ASU requires entities that calculate net asset value to disclose the timing of liquidation of an investee’s assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced the timing publicly. This ASU also adds new requirements, which include the disclosure of the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. The amendments in this ASU are effective for public companies for fiscal years, and interim fiscal periods within those fiscal years, beginning after December 15, 2019. The Company adopted this guidance and it did not have a material impact on the condensed consolidated financial statements.
ASU 2019-04 - Codification Improvements to Topic 326, Financial Instruments - Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments (April 2019)
The amendments in this ASU clarify or correct the guidance in ASC Topic 326, Topic 815 and Topic 825. With respect to Topic 326, ASU 2019-04 addresses a number of issues as it relates to the CECL standard including consideration of accrued interest, recoveries, variable-rate financial instruments, prepayments, extension and renewal options, among other things, in the measurement of expected credit losses. The amendments to Topic 326 have the same effective dates as ASU 2016-13 and the Company is currently evaluating the potential impact of these amendments on the condensed consolidated financial statements. With respect to Topic 815, ASU 2019-04 clarifies issues related to partial-term hedges, hedged debt securities, and transitioning from a quantitative method of assessing hedge effectiveness to a more simplified method. The amendments to Topic 815 are effective for interim and annual reporting periods beginning after December 15, 2019 and are not expected to have a material impact on the condensed consolidated financial statements. With respect to Topic 825, ASU 2019-04 addresses the scope of the guidance, the requirement for remeasurement under ASC Topic 820 when using the measurement alternative, certain disclosure requirements, and which equity securities must be remeasured at historical exchanges rates. The amendments to Topic 825 are effective for interim and annual reporting periods beginning after December 15, 2019 and are not expected to have a material impact on the condensed consolidated financial statements.
Coronavirus Aid, Relief and Economic Security Act (“CARES Act”)
In March 2020 in connection with the implementation of the CARES Act and related provisions, the Company elected the temporary relief in the CARES Act not to apply the guidance in ASC 310-40 on accounting for TDRs to loan modifications related to COVID-19. Section 4013 of the CARES Act further provides that loan modifications due to the impact of COVID-19 that would otherwise be classified as TDRs under GAAP will not be so classified. Modifications within the scope of this relief are in effect from the period beginning March 1, 2020 until the earlier of December 31, 2020 or 60 days after the date on which the national emergency related to the COVID-19 pandemic formally terminates.